Errors in the Conflicts of Interest Section, Figure 2, and Affiliations

No authors listed

Published Erratum

No authors listed. JAMA Oncol. 2023.

. 2023 Sep 1;9(9):1300.

doi: 10.1001/jamaoncol.2023.2810.

No abstract available

Erratum for

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, Smit EF, Cortot AB, Raskin J, Viteri S, Wu YL, Yang JCH, Ahn MJ, Ma R, Zhao J, O'Brate A, Berghoff K, Bruns R, Otto G, Johne A, Felip E, Thomas M. Mazieres J, et al. JAMA Oncol. 2023 Sep 1;9(9):1260-1266. doi: 10.1001/jamaoncol.2023.1962. JAMA Oncol. 2023. PMID: 37270698 Free PMC article. Clinical Trial.

1. Mazieres J, Paik PK, Garassino MC, et al. . Tepotinib treatment in patients with MET exon 14–skipping non–small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial. JAMA Oncol. 2023;e231962. doi:10.1001/jamaoncol.2023.1962 - DOI - PMC - PubMed